Source link : https://newshealth.biz/health-news/fda-approves-cdk4-6-inhibitor-for-her2-positive-breast-cancer/
The FDA approved the CDK4/6 inhibitor palbociclib (Ibrance) as part of a first-line maintenance regimen for hormone receptor (HR)-positive/HER2-positive breast cancer. Approval stipulates use of palbociclib plus trastuzumab — with or without pertuzumab (Perjeta) — and endocrine therapy following induction treatment for adults with locally advanced or metastatic disease. In the open-label phase III PATINA […]
The post FDA Approves CDK4/6 Inhibitor for HER2-Positive Breast Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-24 20:58:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8